{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"563"}],"units":"Participants"}],"title":"Baseline evaluable participants"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"569"}],"units":"Participants"}],"title":"Post-baseline evaluable participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"569"}],"units":"Participants"}],"groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG000","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"NUMBER","populationDescription":"PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Baseline to approximately 55 months","title":"Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}